ArticleDrug design, development and therapy2025
Network Pharmacology Approach to Unveiling the Mechanism of Wolfberry Mulberry Raspberry Decoction in the Treatment of Sepsis-Induced Myocardial Dysfunction.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms ofFood science & nutrition · 2026Article
- Research progress on targeting autophagy pathways with medicinal plants and their active metabolites for the treatment of heart failure.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the mechanisms by which the Wolfberry Mulberry Raspberry Decoction (WMRD) affects Sepsis-Induced Myocardial Dysfunction (SIMD) using network pharmacology and experimental validation. Methods: We explored the TCM Systems Pharmacology Database to gather biological data for WMRD compounds. The GeneCards, PharmGkb, Therapeutic Target Database (TTD), and Online Mendelian Inheritance in Man (OMIM) databases were utilized to identify target proteins associated with SIMD. Overlapping elements between SIMD and drug targets were analyzed. This data was integrated into the STRING platform to visualize protein interactions. Cytoscape software was then used to construct a network diagram illustrating relationships between drug components and their corresponding targets. Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathways analyses were conducted using a database for annotation and visualization. Predictive pathways were validated through experimental studies on cellular and animal models. Results: Network pharmacology analysis identified 58 active compounds of WMRD and revealed that WMRD partially ameliorated SIMD by modulating apoptosis, TNF signaling pathway and IL-17 signaling pathway. Quercetin, one of the main components of WMRD, suppresses apoptosis and oxidative stress in H9C2 cell via regulating the MMP9, TNF-α, IL-1β and BCL/BAX axis. Quercetin increased BCL-2 expression and decreased MMP9, TNF-α, IL-1β, Bax, and Caspase-3 protein expression in H9C2 cells treated with LPS. Moreover, Quercetin attenuated LPS-Induced myocardial injury and apoptosis in SIMD mice model. Therefore, this study suggests that Wolfberry Mulberry Raspberry decoction may be a potential drug for the treatment of septic myocardial injury, in which Quercetin may play an important role. Conclusion: Quercetin, a key component of WMRD, suppressed H9C2 cell apoptosis by dysregulating MMP9, TNF-α, IL-1β, and BCL/BAX axis, highlighting its therapeutic potential in SIMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.